AI Article Synopsis
- The study investigates the relationship between asthma and BMI, as well as the timing of menarche in girls, confirming that asthma is more prevalent in overweight girls.
- It utilizes data from a national birth cohort, assessing asthma at ages 7, 11, 16, and 33 years, and analyzes how changes in BMI over these years relate to asthma.
- Results show a significant association between asthma and BMI across all ages, but early menarche does not significantly contribute to the risk of asthma, especially by age 33.
Article Abstract
Background: Obesity and early menarche have been associated with asthma. In this report, we assess the association of asthma with BMI and with changes in BMI from childhood to early adulthood. In addition, we determine if, in girls, any observed association of asthma with menarche can be explained by BMI.
Methods: In a large national birth cohort, the associations of asthma at age 7, 11, 16 and 33 years with BMI, and of, asthma at age 33 years with changes in BMI from age 7 to age 33 years was assessed using logistic and mixed effects models as appropriate. Associations of asthma with age of menarche in girls were similarly assessed with and without adjustment for BMI.
Results: Information on asthma, BMI, onset of menarche and confounders at all assessments was available for 1968 girls and 2223 boys. Obesity was relatively uncommon (<2%) in childhood. Overweight (BMI 25+) girls had more asthma. Girls with early menarche were more likely to be overweight. At age 11 years, asthma was associated with early menarche (OR = 1.70, 95% CI 1.17-2.47, after adjustment for BMI OR = 1.60, 95% CI 1.10-2.34). Across all ages, asthma was significantly associated with BMI (OR = 1.50, 95% CI 1.18-1.90) but not with early menarche (OR = 1.24, 95% CI 0.95-1.63).
Conclusion: Asthma is more common in overweight girls. Early menarche is more common in overweight girls but this does not explain its association with asthma at age 11 years. Early menarche is not a risk factor for asthma at age 33 years in this cohort.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3109/02770903.2013.799686 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Introduction: The associations between sedentary lifestyles, physical activity and the risk of respiratory diseases are crucial areas of medical and health research. Despite numerous studies, uncertainties and controversies regarding causal relationships persist. We utilized Mendelian randomization (MR) analysis, an advanced statistical tool, to further investigate causal links.
View Article and Find Full Text PDFIntensive Asthma Therapy and Intravenous Magnesium Sulfate in the Emergency Department Management of Pediatric Asthma.
Pediatr Emerg Care
December 2024
From the Division of Emergency Medicine, Department of Pediatrics, Children's Hospital of Michigan, Detroit, MI.
Objective: The aim of the stud is to determine whether intravenous magnesium sulfate (IVMg) is associated with hospitalization and time to albuterol every 4 hours in a cohort of children who received intensive asthma therapy (IAT) in the emergency department (ED).
Methods: This retrospective cohort study included children 2-18 years who received IAT, defined as 3 bronchodilators and corticosteroids within 60 minutes of ED triage, with or without IVMg in the ED between 2019 and 2021. Primary outcome was hospitalization and among hospitalized children, secondary outcome was time to albuterol every 4 hours.
Thiazole-based IL-17 inhibitors discovered by scaffold morphing.
ChemMedChem
December 2024
Novartis Institutes for BioMedical Research Basel, Global Discovery Chemistry, SWITZERLAND.
The pro-inflammatory cytokine interleukin-17A (IL-17) plays an important role in the body's defense against bacterial and fungal infections. However, overexpression of IL-17 has been associated with several diseases, including rheumatoid arthritis, asthma, psoriasis, and even cancer. The role of IL-17 in psoriasis has been confirmed by clinical use of IL-17 antibodies, e.
View Article and Find Full Text PDFHigh Interleukin (IL)-6 is Associated with Lower Lung Function and Increased Likelihood of Metabolic Dysfunction in Asthma.
Pulm Ther
December 2024
Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI, USA.
Introduction: Asthma is a complex condition characterized by airway inflammation. Interleukin-6 (IL-6) plays a significant role in asthma pathogenesis through its effects on T cells and its association with pro-inflammatory responses. Both lung and circulating IL-6 levels are elevated in asthma.
View Article and Find Full Text PDFMedicare Advantage Population in the United States: Outcomes of Patients with Asthma Treated with ICS/LABA Before and After Initiation with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI).
Adv Ther
December 2024
US Value Evidence and Outcomes, GSK, Collegeville, PA, USA.
Introduction: The clinical benefits of fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) have been demonstrated in clinical trials. There is limited evidence regarding the effectiveness and economic outcomes associated with FF/UMEC/VI use in US clinical practice. This real-world study assessed asthma-related exacerbations, healthcare resource utilization (HRU), and healthcare costs among a Medicare Advantage-insured population before and after initiation of FF/UMEC/VI in patients with asthma previously treated with an inhaled corticosteroid/long-acting β-agonist (ICS/LABA).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!